Barrie Chubb

7PUBLICATIONS
12CO-AUTHORS
PharmacogenomicsExercise physiologyGene and molecular therapyEconomic models and forecasting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 20, 2025
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.

Peter Rossing, Morten Lindhardt, Christian Klyver Tikkanen

|Aug 01, 2023
Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.

Sasha Berry, Barrie Chubb, Annabel Acs

|Nov 26, 2022
An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal-Bolus Insulin in Type 2 Diabetes.

Ildiko Lingvay, Andrei-Mircea Catarig, Jack Lawson

|Oct 17, 2022
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.

Marc Evans, Barrie Chubb, Samuel J P Malkin

|Sep 17, 2022
The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.

Adie Viljoen, Barrie Chubb, Samuel J P Malkin

|Jul 21, 2021
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.

Richard E Pratley, Andrei-Mircea Catarig, Ildiko Lingvay

Pageof 2

Frequent Collaborators

3 joint publications

Samuel J P Malkin

2 joint publications

Barnaby Hunt

1 joint publications

Richard E Pratley

1 joint publications

Ildiko Lingvay